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Background/aim: Studies regarding effectiveness of anakinra and tocilizumab treatments in coronavirus disease 2019 (COVID-19)
have contradictory results. Furthermore, there is scarce comparative data regarding superiority of any agent. To further elucidate any
superiority between these two agents, we retrospectively investigated and compared outcomes in hospitalized COVID-19 patients of our
inpatient cohort who received anakinra or tocilizumab.
Materials and methods: This study was designed as a single-center, retrospective, cross-sectional cohort study. Hospitalized patients
with confirmed diagnosis of COVID-19 who had Brescia-COVID respiratory severity scale score ≥3 and hyperinflammation (defined
as elevation of C reactive protein ≥50 g/L or ferritin ≥700 ng/mL) and received anakinra or tocilizumab in addition to standard care
were enrolled in the study. Length of hospital stay after initiation of antiinflammatory treatment, need for mechanical ventilation, need
for intensive care unit admission, mortality were set as primary outcomes and compared between tocilizumab and anakinra recipients
after propensity score matching.
Results: One hundred and six patients were placed in each group after propensity score matching. In the anakinra group, relative risk
reduction for intensive care unit admission was 50% when compared to the tocilizumab group and the number needed to treat to avert
an intensive care unit admission was 3 (95% CI, 2–5). In terms of mortality, a 52% relative risk reduction was observed with anakinra
treatment and the number needed to treat to avert an intensive care unit admission was 8 (95% CI, 4–50). Significantly more patients
were observed to receive glucocorticoids in the anakinra group.
Conclusion: Anakinra administration in severe COVID-19 patients was significantly associated with better survival and greater clinical
improvement compared to the tocilizumab administration in our study. Increased rate of glucocorticoid use in the anakinra group
might have contributed to better outcomes.
Key words: COVID-19, cytokine storm, hyperinflammation, anakinra, tocilizumab
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1. Introduction
Coronavirus disease 2019 (COVID-19) has a wide
spectrum of clinical presentations with disease course
varying from asymptomatic infection to severe pneumonia
causing death [1]. Approximately 5% of COVID-19
cases need intensive care due to systemic inflammation
and acute respiratory distress syndrome (ARDS) with a
mortality rate of 1%–2% [2]. Proinflammatory cytokines
such as interferon (IFN) γ, tumor necrosis factor (TNF)-α,
interleukin (IL)-6, IL-1β, and IL-18 play a major role in
immune response to viral infections; however, triggering
of a hyperimmune state characterized by excessive and
dysregulated release of these cytokines, so called “cytokine
storm”, has been defined as a major cause of mortality and
morbidity in COVID-19.
Cytokine storm has been revealed to correlate with
disease severity in hospitalized COVID-19 patients and
defined as a prognostic factor for worse outcomes [3-5].
Therefore, undelayed recognition of cytokine storm and
administration of appropriate antiinflammatory agents
with optimal timing seems to be crucial. Considerable
knowledge regarding antiinflammatory treatment
strategies such as systemic corticosteroids, colchicine,
anticytokine agents, and intravenous immunoglobulins
has been accumulated in the literature during the
pandemic; however, precise approach for management of
cytokine storm is yet to be fully clarified.
Interleukin-1 and IL-6 are proinflammatory cytokines
which have been demonstrated to be major contributors
to development of hyperinflammatory response in
COVID-19. Interleukin-1a is one of the initial cytokines
released in COVID-19, inducing IL-6, TNF-α, granulocytemacrophage colony stimulating factor (GM-CSF), and IL17 expression after binding to its receptor [6]. Likewise,
overproduction of IL-6 reported to drive the immune
dysregulation in severe COVID-19 patients [7]. Both these
cytokines seem to be potential targets for management of
cytokine storm in COVID-19. Accordingly, blockers of
both IL-1 and IL-6 have been investigated in treatment of
COVID-19.
Tocilizumab is a recombinant humanized monoclonal
antibody directed against soluble and membrane-bound
IL-6 receptors, and anakinra is a recombinant human IL-1
receptor antagonist. Effectiveness of both tocilizumab
and anakinra on outcomes has been reported alongside
contradictory results; nevertheless, both agents have been
used in management of COVID-19 during the pandemic
[8-19]. In addition to the controversy surrounding the
effectiveness of these agents, there is scarce comparative
data regarding superiority of any anticytokine agent in
COVID-19 [20].

To further elucidate any superiority between these two
agents, here in this study, we retrospectively investigated
and compared outcomes in hospitalized COVID-19
patients of our inpatient cohort who received anakinra or
tocilizumab treatments.
2. Materials and methods
This is a single-center, retrospective, cross-sectional
study. Ethical approval of the study was obtained from the
Ethics Committee of Ankara City Hospital. Hospitalized
adult COVID-19 patients between April 1 and December
31, 2020, from Ankara City Hospital Internal Medicine,
Infectious Diseases and Clinical Microbiology, Critical
Care clinics were retrospectively investigated. Among these,
patients with confirmed diagnosis of COVID-19 (positive
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) polymerase chain reaction test with compatible
findings in chest X-ray or computed tomography) who
had Brescia-COVID respiratory severity scale (BCRSS)
score ≥3 and hyperinflammation (defined as elevation of
C-reactive protein (CRP) ≥50 mg/L or ferritin ≥700 ng/
mL) and received anakinra or tocilizumab treatments in
addition to standard care were enrolled in the study [21].
Patients who were under the age of 18, pregnant, or had
a history of biologic agent or systemic glucocorticoid use
prior to COVID-19, a malignant disease, or a psychiatric
disorder at the time of hospitalization were excluded.
In our center during the pandemic, hospitalization,
treatment, management, and discharge decisions of the
patients were made according to the national guidelines
prepared by Turkish Health Ministry1. In accordance
with these guidelines, standard care in our center
comprised hydroxychloroquine (400 mg/day without
loading for 5 days and continued for 10 days in severe
cases), low molecular weight heparin, acetylsalicylic acid,
favipiravir (3200 mg on day 1 and 1200 mg on days 2–5).
All patients in this study were managed in guidance with
these regulations and received standard care medications
if not contraindicated. Likewise, administration of
antiinflammatory treatment agents including systemic
glucocorticoids, tocilizumab, anakinra, and intravenous
immunoglobulins were decided according to national
guidelines. Anakinra dose varied from 2 to 10 mg/kg and
administered subcutaneously in divided doses for every 6
h [16]. Duration (days) of anakinra treatment was decided
by attending resident and individualized according to
response and side effects. Tocilizumab was administered
a single dose of 8 mg/kg via peripheral intravenous route
[11,12]. After initial administration, a second dose was
administered after 24/48 h in refractory patients if deemed
necessary by attending resident [12,22].

Ministry of Health, Turkey. Guidance To Covid-19 (SARS Cov2 Infection) (2021). Website https://hsgm.saglik.gov.tr/tr/covid-19-ingilizce-dokumanlar.html [accessed 27 January 2021]
1
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Demographic, clinical, laboratory, imaging, treatment,
and outcome data were collected using a standardized
form. All data were saved by the same physician (OK).
Patients were grouped into two as anakinra recipients
and tocilizumab recipients. Length of hospital stay
after initiation of antiinflammatory treatment, need for
mechanical ventilation, need for intensive care unit (ICU)
admission, and mortality were set as primary outcomes
and compared between groups after propensity score
(PPS) matching.
Data were analyzed using SPSS v. 22.0 software except
for propensity score matching which was done with the
statistical software R (version 3.5.1, The R Foundation for
statistical computing, Vienna, Austria). Shapiro–Wilk’s
test was used to determine the distribution of the data. The
distribution of continuous data was expressed as mean
± standard deviation. Continuous variables that did not
conform to normal distribution were expressed as median
and interquartile range (IQR) values. Continuous variable
was compared by using either Student’s t-test or the Mann–
Whitney U test according to normality. For categorical
variables, χ2 test was used and the outcomes were expressed
as number and percentages. Relative risk (RR) values and
their 95% confidence interval (CI) were calculated through
crosstabs. p-values below 0.05 were considered statistically
significant. We calculated the propensity between two
groups on the basis number of days from symptom onset
to administration of anticytokine treatment used in the
logistic-regression analysis. We matched each patient in
the tocilizumab group to the patient in the anakinra group
(1:1) with the closest propensity score, using a greedy
nearest neighbor matching without replacement within
0.001 caliper widths.
3. Results
A total of 360 patients were enrolled in the study
(120 anakinra recipients, 240 tocilizumab recipients).
Demographics, comorbidities, COVID-19 symptoms,
and days from symptom onset to administration of
anticytokine treatment are given in Table 1. Days
from symptom onset to administration of anakinra or
tocilizumab were significantly different between groups
(median (IQR) 10 (6) vs 8 (6) day, p < 0.0001, respectively).
After PPS matching based on duration of symptom onset,
106 patients were placed in both groups. No significant
differences were observed between groups in means of sex
and comorbidities before and after PPS matching (Table
1). Cough (60.4% vs 42.5%, p = 0.013) and dyspnea (75.5%
vs 55.7%, p = 0.04) were significantly more common in the
tocilizumab group after matching.
Baseline and last laboratory parameters of both
groups before and after PPS matching are given in Table
2. Baseline CRP, D-dimer, and lactate dehydrogenase
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levels remained significantly higher in the tocilizumab
group after PPS match. In last parameters, CRP levels
were similar between groups, fibrinogen was higher, and
D-dimer was significantly lower in the anakinra group
after PPS match (Table 2).
Initial median (IQR) anakinra dose was found to be
600 (200) mg and median (IQR) duration of treatment was
7 (4) days before and after PPS matching. Median (IQR)
tocilizumab dose for first administration was 400 (200) mg
and median (IQR) duration of treatment was 2 (1) days.
Primary outcomes are presented in Table 3. Duration
of hospital stay after onset of treatment administration
was significantly longer in the anakinra group both before
and after PPS matching (median (IQR), 11 (11) days vs 10
(8) days, p = 0.03, after PPS matching). However, length
of hospital stay after end of anticytokine treatment was
reduced in the anakinra group (median (IQR), 4 (12)
days vs 8.5 (9) days, p ≤ 0.0001, after PPS matching).
Mechanical ventilation rates were similar between groups.
Rate of intensive care unit admission was lower in the
anakinra group both before (35% vs 66.7%, p < 0.001) and
after (33% vs 66%, p < 0.001) PPS matching. Likewise,
mortality levels were lower in the anakinra group before
and after PPS matching (14.2% vs 22.9%, p = 0.05 and
11.3% vs 23.6%, p = 0.029, respectively).
Rates of favipiravir, hydroxychloroquine, and
glucocorticoids are presented in Table 4. After PPS,
frequency of hydroxychloroquine use was similar between
groups and all patients were observed to receive favipiravir.
Rate of glucocorticoid use was significantly higher in the
anakinra group (98.1% vs 79.2%, p < 0.0001).
After propensity score matching, in the intentionto-treat (ITT) population, intensive care unit admission
developed in 35 of 106 patients (33%) who received
anakinra and in 70 of 106 patients (66%) who received
tocilizumab (relative risk, 0.50; 95% CI, 0.36 to 0.67; p<
0.001). The relative risk reduction with anakinra was
50% and the number needed to treat (NNT) to avert an
intensive care unit admission was found to be 3 (95%
CI, 2 to 5). After propensity score matching, in the ITT
population, mortality developed in 12 of 106 patients
(11.3%) who received anakinra and in 25 of 106 patients
(23.6%) who received tocilizumab (relative risk, 0.48; 95%
CI, 0.25 to 0.90; p = 0.029). The relative risk reduction with
anakinra was 52% and the NNT to avert a mortality was
found to be 8 (95% CI, 4 to 50).
4. Discussion
In this retrospective cohort study, we evaluated the
outcomes of tocilizumab and anakinra treatments in
severe (BCRSS ≥ 3) COVID-19 patients. Both tocilizumab
and anakinra groups were similar in terms of age, sex,
and comorbidity. After PPS matching based on days from
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symptom onset to initiation of anticytokine treatment, rates
of mortality and admission to ICU were significantly lower
in the anakinra group. Rate of additional glucocorticoid
use was significantly higher in the anakinra group.
COVID-19 generally causes mild illness; however,
a substantial number of patients suffer from severe
respiratory distress leading to death [23]. SARS-CoV-2
induces a cytokine storm similar to macrophage activation
syndrome characterized by excessive expression of
proinflammatory cytokines [24]. Viral proteins induce
inflammasome and caspase-1 activation via binding
to toll-like receptors. Caspase 1 cleaves inactive proIL-1β to active IL-1β which is an important mediator
for lung inflammation and fibrosis in COVID-19 [25].

Furthermore, IL-1β mediates Il-6 synthesis, a key
proinflammatory cytokine in COVID-19 cytokine
storm and a potent inducer of CRP [26]. Virus-infected
monocytes, macrophages, and dendritic cells further
induce expression of IL-6 and other proinflammatory
cytokines. Presence of such hyperinflammatory state is
accepted as an indicator for a COVID-19 infection [27].
Growing evidence suggest that severe COVID-19 patients
have higher plasma levels of cytokines, such as IL-1β,
IL-6, and IL-10, and concentration of these cytokines
in the plasma may differentiate mild, moderate, and
severe cases [28,29]. Cytokine storm has been associated
with development of ARDS, disseminated intravascular
coagulation, and multiorgan failure [27].

Table 1. Demographics, comorbidities, and COVID-19 symptoms in tocilizumab and anakinra recipients.
All patients

After propensity score

Anakinra
(n:120)

Tocilizumab
(n: 240)

p

Anakinra
(n: 106)

Tocilizumab
(n: 106)

p

Male sex, n (%)

98 (81.7)

182 (75.8)

0.209

87 (82.1)

83 (78.3)

0.491

Median age, years, (IQR)

57 (15)

59 (16)

0.109

56 (15)

59 (16)

0.127

Cough

51 (42.5)

130 (54.2)

0.037

45 (42.5)

64 (60.4)

0.013

Fever

66 (55)

126 (52.5)

0.654

62 (58.5)

56 (52.8)

0.49

Dyspnea

70 (58.3)

158 (65.8)

0.164

59 (55.7)

80 (75.5)

0.04

Headache

12 (10)

15 (6.3)

0.203

11 (10.4)

7 (6.6)

0.46

Back pain

7 (5.8)

4 (1.7)

0.03

7 (6.6)

1 (0.9)

0.06

Arthralgia

5 (4.2)

12 (5)

0.725

5 (4.7)

7 (6.6)

0.76

Myalgia

67 (55.8)

95 (39.6)

0.003

61 (57.5)

43 (40.6)

0.01

Anosmia

2 (1.7)

15 (6.3)

0.065

2 (1.9)

6 (5.7)

0.28

Ageusia

1 (0.8)

24 (10)

0.001

1 (0.9)

10 (9.4)

0.01

Patients with ≥1
comorbidities

77 (64.2)

154 (64.2)

1

66 (62.3)

66 (62.3)

1

Hypertension

51 (42.5)

104 (43.3)

0.88

43 (40.6)

43 (40.6)

1

Diabetes

31 (25.8)

73 (30.4)

0.366

26 (24.5)

32 (30.2)

0.44

Asthma

9 (7.5)

15 (6.3)

0.654

9 (8.5)

7 (6.6)

0.79

COPD

4 (3.3)

13 (5.4)

0.38

4 (3.8)

7 (6.6)

0.53

CHD

27 (22.5)

45 (18.8)

0.402

19 (17.9)

20 (18.9)

1

Renal disease

5 (4.2)

12 (5)

0.725

3 (2.8)

5 (4.7)

0.72

Days from symptom onset to treatment
administration , median (IQR)

10 (6)

8 (6)

<0.0001

10 (4)

10 (4)

1

COVID-19 symptoms, n (%)

Comorbidities, n (%)

n: number; IQR: interquartile range; COVID-19: coronavirus disease 2019; COPD: chronic obstructive pulmonary disease; CHD: chronic
heart disease

1489

1490

35.5 (31.5)

718 (829)

9.74 (5.06)

0.59 (0.39)

35.9 (7.52)

78.5 (110.25) 119.5 (213)

0.63 (1.41)

5.46 (2.36)

13.4 (1.8)

229 (141)

ESR, mm/h

Ferritin, μg/L

WBC, 10 / L

Lymphocyte, 10 / L

Albumin, g/dL

CK, U/L

D-dimer , mg/L

Fibrinogen,g/L

Hg, g/dL

Platelet, 10 /L

274.5 (165)

13.2 (2.2)

5.68 (2.23)

1.09 (1.89)

35.24 (6)

0.76 (0.46)

8 (4.68)

950 (931)

51 (39.75)

126 (90.5)

476 (245)

44 (42)

0.002

0.272

7.59 (3.9)

873 (837)

46.5 (46.5)

36.4 (6.4)

5.6 (2.47)

236 (136)

273 (160)

13.35 (1.9) 13.1 (2.4)

5.6 (2.41)

1.14 (2.15)

101 (132)

35 (6.5)

0.59 (0.39) 0.77 (0.45)

9.9 (5.4)

723 (776)

36 (35.5)

<0.0001 0.59 (1.2)
0.494

492 (244)

43 (43)

83.5 (97.7) 127.5 (87.7)

398 (189)

45 (42)

<0.0001 79 (119)

0.338

<0.001

0.001

0.032

<0.001

<0.001

0.001

0.329

48 (44)

0.89 (0.27) 0.82 (0.28)

<0.0001 41 (30)

0.034

0.02

0.078

0.43

<0.001

0.03

0.018

0.001

<0.001

0.188

0.01

0.003

0.001

0.582

0.07

0.027

285 (148)

13 (2.9)

3.79 (1.63)

0.49 (0.87)

46 (68)

35.8 (10.2)

1.51 (1.05)

8.61 (4.6)

407 (515)

24 (32)

8 (25.2)

301 (145)

64 (56)

34 (28)

0.87 (0.29)

279 (148)

13 (2.7)

2.69 (1.97)

0.97 (2.64)

51 (113)

35 (7)

1.44 (1.03)

8.06 (6.1)

465 (577)

17 (35)

5 (18)

317 (276)

64.5 (85)

37 (52)

0.85 (0.35)

49 (67)

37.02 (9.6)

1.53 (0.87)

8.45 (4.53)

405 (473)

25 (37)

7 (21.5)

292 (133)

66.5 (54)

35 (28)

0.88 (0.25)

Anakinra
(n:106)

0.639

0.92

2.69 (1.95)

0.87 (3.35)

46 (58)

34.2 (7.2

1.41 (0.99)

7.9 (6.78)

429 (469)

16.5 (34)

5 (19)

312 (284)

63.5 (73)

36 (50)

0.86 (0.33)

286.5 (140)

266 (167)

0.414

0.623

<0.0001

<0.0001

0.855

0.036

0.124

0.438

0.792

0.067

0.196

0.270

0.779

0.289

0.649

Tocilizumab
p
(n:106)

13.15 (2.65) 12.9 (2.53)

<0.0001 3.9 (1.62)

<0.0001 0.46 (0.75)

0.163

0.151

0.328

0.565

0.623

0.071

0.037

0.156

0.889

0.132

0.711

Tocilizumab
p
(n:240)

After propensity score

AST: aspartate transaminase; ALT: alanine transaminase; LDH: lactate dehydrogenase; CRP: c-reactive protein; ESR: eritrocyte sedimentation rate; WBC: white blood cells; CK: creatine
kinase; Hg: hemoglobin

9

81 (99)

CRP, mg/L

9

400 (219)

LDH, U/L

9

44 (42)

ALT, U/L

50 (42)

40 (30)

AST, U/L

0.82 (0.3)

0.88 (0.3)

Creatinin, mg/dL

Anakinra
(n:120)

Anakinra
(n:106)

Anakinra
(n:120)

Tocilizumab
p
(n:106)

Before propensity score

After propensity score

Before propensity score

Tocilizumab
p
(n:240)

Last

Baseline

Table 2. Baseline and last laboratory parameters in tocilizumab and anakinra recipients.
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Table 3. Outcomes in tocilizumab and anakinra recipients.
All patients
Anakinra
(n:120)

After propensity score
Tocilizumab
(n:240)

p

Anakinra
(n:106)

Tocilizumab
(n:106)

p

Length of hospital stay after treatment initiation, days,
12 (12)
median (IQR)

11 (9)

0.027

11 (11)

10 (8)

0.03

Length of hospital stay after treatment ends, days,
median (IQR)

4 (12)

9 (9)

<0.0001 4 (12)

8.5 (9)

<0.0001

Rate of invasive mechanical ventilation, n(%)

32 (26.7)

68 (28.3)

0.73

30 (28.3)

0.53

Rate of intensive care unit admission, n(%)

42 (35)

160 (66.7)

<0.0001 35 (33)

70 (66)

<0.001

Mortality, n(%)

17 (14.2)

55 (22.9)

0.05

25 (23.6)

0.029

25 (23.6)
12 (11.3)

n:number; IQR: interquartile range

Table 4. Frequencies of favipiravir, hydroxychloroquine, and glucocorticoid use in tocilizumab and anakinra recipients.
All patients

After propensity score

Anakinra
(n:120)

Tocilizumab
(n: 240)

p

Anakinra
(n: 106)

Tocilizumab
(n: 106)

p

Hydroxychloroquine, n (%)

81 (67.5)

136 (56.7)

0.048

77 (72.6)

67 (63.2)

0.141

Favipiravir, n (%)

118 (98.3)

240 (100)

0.110

106 (100)

106 (100)

1.000

Glucocorticoid, n (%)

116 (96.7)

195 (81.3)

<0.0001

104 (98.1)

84 (79.2)

<0.0001

Immune dysregulation in COVID-19 is reported
to be mediated by IL-6 and in animal models low IL-6
concentrations were associated with less severe acute
lung injury [30]. Interleukin-6 may be a potential target
in treatment of COVID-19–related cytokine storm.
Accordingly, tocilizumab treatment reported to reduce the
need for mechanical ventilation, improve hypoxemia, and
regress imaging findings [13]. Similarly, Toniati et al. [14]
related tocilizumab treatment with clinic improvement in
¾ of 100 COVID-19 patients. In a retrospective cohort of
544 patients, Guaraldi et al. [15] reported a significantly
lower death rate in the tocilizumab group compared to
the control group (7% vs 20%, respectively). Among 764
COVID-19 patients in the ICU, Biran et al. [31] reported
a significant decrease in the mortality rate and risk of
mechanical ventilation with tocilizumab. In contrast to
these observational findings, in five randomized controlled
trials, no superiority against placebo or standard care
with tocilizumab was observed except for EMPACTA
study which revealed benefit of tocilizumab in reducing
the likelihood of progression to requiring mechanical

ventilation or death [8-12]. In addition, a systematic
review and metaanalysis of seven retrospective studies
showed that there is no statistically significant difference
between tocilizumab and standard care in terms of allcause mortality (odds ratio (OR): 0.62; 95% CI: 0.31–1.22)
and ICU admission (relative risk (RR): 1.51; 95% CI: 0.33–
6.78) [32].
Interleukin-1 also seems to be an important cytokine
in pathogenesis of COVID-19–related cytokine storm.
Increased IL-1α and IL-1β expression was revealed in
severe COVID-19 patients prior to development of
respiratory distress [24]. Furthermore, COVID-19–
related cytokine storm shares similarities with other
autoinflammatory
conditions
characterized
by
hyperinflammation such as adult onset Still’s disease and
macrophage activation syndrome in which IL-1 pathway
is a major target for treatment [33,34]. Therefore, anakinra
has been considered for treatment of COVID-19–
related cytokine storm and several studies demonstrated
beneficial effects [35]. A retrospective study analyzed 29
severe COVID-19 patients treated intravenously with
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anakinra and the majority of which had pO2/FiO2 less
than 100 mmHg [16]. The mortality rate of this study
was 10% on the 21st day which was significantly lower
compared to the 16 comparator patients with a mortality
rate of 44% who received standard-of-care treatment. Huet
et al. [17] reported reduced mortality and mechanical
ventilation rates in severe COVID-19 pneumonia
with a 10-day course of anakinra when compared to
nonusers. Likewise, Balkhair et al. [18] related anakinra
treatment with reduced mortality and increased rate of
successful weaning from mechanical ventilation in severe
COVID-19 patients. However, in randomized controlled
CORIMUNO-ANA-1 study, no benefit of anakinra was
observed in mild and moderate COVID-19 patients on
invasive or noninvasive mechanical ventilation support
[19].
There is scarce comparative data in the literature
regarding superiority of anakinra and tocilizumab to
each other in management of COVID-19. In a recently
published retrospective study with comparison of IL-1
inhibition (anakinra) and IL-6 inhibition (tocilizumab
or sarilumab) strategies, IL-1 inhibition but not IL-6
inhibition was reported to reduce mortality, respiratory
insufficiency, and hyperinflammation significantly in
hospitalized COVID-19 patients [20]. In our study, we
observed better outcomes in means of mortality and ICU
admission rates with anakinra. In the anakinra group,
relative risk reduction for ICU admission was 50% when
compared to tocilizumab group and NNT to avert an ICU
admission was 3 (95% CI, 2 to 5). In terms of mortality,
a 52% relative risk reduction was observed with anakinra
treatment and NNT to avert was 8 (95% CI, 4 to 50).
Hospital stay after initiation of anticytokine treatment
was shorter in tocilizumab group (10 (8) days vs 11 (11)
days, p = 0.003) and we assume this may be related to
increased mortality in tocilizumab group. When baseline
and last laboratory parameters were evaluated (Table
2), tocilizumab seemed to provide better reduction in
inflammatory markers; however, this reduction was not
coherent with outcomes since anakinra group had reduced
mortality and ICU admission.
In management of autoinflammatory conditions,
anakinra was generally administered with a dose of 100
mg/day subcutaneously [36]. Several data suggest higher
doses (100–400 mg/day) and intravenous administration
in management of life threatening hyperinflammatory
conditions such as macrophage activation syndrome,
and due to short half-life (3 h), diving daily total dose to
6 h intervals are suggested in severe conditions [37,38].
In our study, median (IQR) anakinra dose at the onset
of treatment was 600 (200) mg/day and median (IQR)
duration of treatment was 7 (4) days.
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The RECOVERY group demonstrated effects
of dexamethasone on mortality in COVID-19 and
glucocorticoids have been used widespread ever since in
treatment of COVID-19 [39]. In our study, in the anakinra
group, rate of glucocorticoid use was significantly higher,
which may indicate contributory effects of glucocorticoid
use and may imply better outcomes with combination
of anakinra and glucocorticoids when compared to
tocilizumab. This result may be due to the fact that
beneficial effects of tocilizumab in COVID-19 were
reported earlier than use of anakinra and glucocorticoids.
There are several limitations in our study. Firstly, this
was a retrospective observational study, which might
aggravate the risk of bias and causal inferences cannot
be drawn because of inherent known and unknown
confounders. Secondly, there was a possibility of sampling
bias since we obtained data from a convenience sample. A
major limitation was that the use of glucocorticoids, even
after PPS matching, was more frequent in the anakinra
group; therefore, it cannot be differentiated whether
better outcomes in the anakinra group was a result of
anakinra use or anakinra and glucocorticoid combination.
Additionally, the frequency of cough, dyspnea, and baseline
levels of CRP, fibrinogen, and D-dimer were higher in the
tocilizumab group, so we cannot elude the possibility of
higher disease severity in the tocilizumab group. Finally,
adverse effects were not evaluated for neither of the agents.
In conclusion, in our study, survival was better and
clinical improvement was greater in severe COVID-19
patients who received anakinra when compared to
those who received tocilizumab. Glucocorticoid use was
significantly more frequent in the anakinra group, which
may be indicative of better outcomes with anakinra and
glucocorticoid combination. Furthermore, there was a
chance that disease severity was higher in the tocilizumab
recipients. There are several factors which may interfere
with effectiveness of anticytokine treatments in COVID-19
such as dosing and timing of initiation. Future studies are
needed to optimize anticytokine treatment strategies in
COVID-19.
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